Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Binding Site's Freelite approved in Japan

This article was originally published in Clinica

Executive Summary

The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved The Binding Site's Freelite assay. The test is used to detect and monitor multiple myeloma (MM) and related plasma cell disorders. Freelite measures levels of free light chains (molecular components of immunoglobulins) in serum, which are higher in patients with MM. Levels drop if a patient is responding well to treatment. Freelite has been approved in the US for diagnosing MM since 2001 and Birmingham, UK-based The Binding Site also markets the test in Europe. Meanwhile, the US National Comprehensive Cancer Network has recommended Freelite in its latest guidelines for the initial diagnostic workup of MM and related disorders.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts